drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Recombinant humanized anti-CD20 monoclonal antibody administered subcutaneously; depletes CD20+ B cells via ADCC, CDC, and apoptosis to reduce autoantibody production. Evaluated in adults with primary membranous nephropathy (Phase I; 350–1000 mg on Days 1 and 15).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Monoclonal Antibodies, Humanized
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Humanized anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20+ B lymphocytes via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis, thereby reducing pathogenic autoantibody production.
drug_name
B007
nct_id_drug_ref
NCT05668403